



CNSide[™]

CLEARING THE WAY

FOR THE DIAGNOSIS AND MANAGEMENT OF BRAIN METASTASES
IN PATIENTS WITH BREAST AND LUNG CANCER

The CNSide[™] assay is not an FDA cleared or approved assay. It is a Biocept lab developed test and its performance characteristics were determined in Biocept's CLIA-certified, CAP-approved laboratory.

Biocept

TO MEET THE CHALLENGE OF
DIAGNOSING AND TREATING
METASTATIC BRAIN TUMORS

ASK THE QUESTION:
IS THERE A TUMOR?
IS THERE A TREATMENT?
IS THERE A TREND?

YES

Now there's a better way to know.



NO



**A NEW ASSAY.
A BETTER ANSWER.**

Introducing CNSide™

A diagnostic assay providing answers to questions current diagnostic tests cannot reliably address:

Is there a tumor?

- CNSide can detect and quantify tumor cells in cerebrospinal fluid in patients with breast or lung cancer and suspected brain metastasis

Is there a treatment?

- CNSide can identify actionable targets for treatment

Is there a trend?

- CNSide can monitor tumor cell count, response to therapy and disease progression



A SIGNIFICANT ADVANCE VS. CSF CYTOLOGY AND IMAGING

CNSide™ is a novel combination of cell-based and cell-free assays utilizing proprietary assay technology

- CNSide is quantitative, while cytology and imaging are qualitative
- CNSide is more sensitive and can detect a higher percentage of tumor cells than cytology¹
- CNSide detected tumor cells in approximately 80% of cases with suspected disease in one study compared with approximately 50% of cases examined by CSF cytology¹



CASE STUDY

REAL-WORLD ANSWERS TO QUESTIONS

BACKGROUND

- 41-year-old female patient with a history of breast cancer presented with neurological symptoms—headache, double vision and seizures
- Imaging suggested signs of brain metastases
- CSF cytology was indeterminate
- Oncologist ordered CNSide™

CNSide RESULTS

- >25,000 CSF tumor cells detected
- Biomarker analysis positive for HER2 (negative in primary tumor)


DECISION IMPACT

- Patient started on intrathecal trastuzumab
- Repeated testing demonstrated a significant and sustained decrease in CSF tumor cell count



CASE STUDY

**IS THERE A TUMOR? YES.
IS THERE A TREATMENT? YES.
IS THERE A TREND? YES.**



The identification of CSF tumor cells and an actionable biomarker gave the physician and patient confidence. The tumor responded to treatment and the patient resumed an active life.

Approximately 50% of brain metastases have actionable mutations not detected in the primary tumor²

**IS THERE A TUMOR?
IS THERE A TREATMENT?
IS THERE A TREND?**

WHEN YOU NEED AN ANSWER
TO YOUR QUESTIONS INVOLVING
BRAIN METASTASES, THERE
IS NO SUBSTITUTE FOR THE
CNSide ASSAY.

YES





Clearing the way to better outcomes.



Biocept, Inc.
9955 Mesa Rim Road
San Diego, CA 92121

© 2021 Biocept, Inc. All rights reserved.
CNSide is a trademark of Biocept, Inc.

MKTG-0096.01
www.Biocept.com